
The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis. The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.
Pyridines, Telacebec, R, Imidazoles, Infectious and parasitic diseases, RC109-216, tuberculosis and other mycobacteria, Mycobacterium leprae, Piperidines, Leprosy, Research Letter, Medicine, :Medicine [Science], telacebec, Hansen disease, bacteria, leprosy
Pyridines, Telacebec, R, Imidazoles, Infectious and parasitic diseases, RC109-216, tuberculosis and other mycobacteria, Mycobacterium leprae, Piperidines, Leprosy, Research Letter, Medicine, :Medicine [Science], telacebec, Hansen disease, bacteria, leprosy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 15 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
